For free samples, call 1-866-318-6977

For free samples, call 1-866-318-6977

RESOURCES FOR PATIENTS GETTING STARTED ON THE SUBCUTANEOUS (SC) FORMULATION OF COSENTYX®

Patient Brochures

The following resources will help guide patients through the process of getting started on the SC formulation of COSENTYX.

Sensoready Pen

Quick Supplemental Tips for Using the Sensoready® and UnoReady® Pens

Helpful tips to prepare patients to use the Sensoready and UnoReady pens, including step-by-step instructions for use and information about sharps disposal

Insurance Patient Brochure

Insurance Patient Brochure

Information to help patients navigate any changes in their insurance plan and avoid disruptions in their treatment with COSENTYX

COSENTYX Medicare Coverage FAQ Brochure

COSENTYX Medicare Coverage FAQ Brochure

Plaque Psoriasis (PsO) Patient Brochure

Plaque Psoriasis (PsO) Patient Brochure

Educates patients on the efficacy and safety of COSENTYX in PsO

Psoriatic Arthritis (PsA) Patient Brochure

Psoriatic Arthritis (PsA) Patient Brochure

Educates patients on the efficacy and safety of COSENTYX in PsA

Psoriatic Arthritis (PsA) Patient Brochure (en español)

Psoriatic Arthritis (PsA) Patient Brochure (en español)

AS and nr-axSpA Patient Brochure

AS and nr-axSpA Patient Brochure

Educates patients on the efficacy and safety of COSENTYX in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)

 AS & nr-axSpA Patient Brochure (en español)

AS & nr-axSpA Patient Brochure
(en español)

Hidradenitis Suppurativa (HS) Patient Brochure

Hidradenitis Suppurativa (HS) Patient Brochure

Educates patients on the efficacy and safety of COSENTYX in HS

HS Patient Brochure (en español)

HS Patient Brochure
(en español)

Pediatric Patient Brochure

Pediatric Patient Brochure

Pediatric Patient Brochure (en español)

Pediatric Patient Brochure
(en español)

COSENTYX Patient Letter Checklist

COSENTYX Patient Letter Checklist

Provides patients with a list of suggested information to include when writing to their health plan

Videos

Video Thumbnail

Supplemental UnoReady Pen Injection Demonstration Video

Video Thumbnail

Supplemental Sensoready Pen Injection Demonstration Video

Video Thumbnail

Supplemental Prefilled Syringe Injection Demonstration Video

COSENTYX YouTube Channel

See more COSENTYX patient videos on our YouTube page.

Key Contacts

Patients can use the information below to reach out with questions about their treatment or support.

Monday – Friday, excluding holidays,
8:00 AM – 8:00 PM ET

T: 1-844-COSENTYX (1-844-267-3689)

F: 1-844-666-1366 or 1-800-343-9117

Monday – Friday, excluding holidays,
8:00 AM – 8:00 PM ET

T: 1-844-COSENTYX (1-844-267-3689)

*Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.

Sensoready and UnoReady are registered trademarks of Novartis AG.

3/24  304232

Expand ISI

INDICATIONS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

WARNINGS AND PRECAUTIONS

Infections

Collapse ISI

INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis (AS).

COSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.

COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (HS).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.

WARNINGS AND PRECAUTIONS

Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials in subjects with moderate to severe PsO, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed in subjects treated with COSENTYX compared to placebo-treated subjects. A similar increase in risk of infection in subjects treated with COSENTYX was seen in placebo‑controlled trials in subjects with PsA, AS and nr-axSpA. The incidence of some types of infections, including fungal infections, appeared to be dose‑dependent in clinical trials.

In the postmarketing setting, serious and some fatal infections have been reported in patients treated with COSENTYX.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients closely for signs and symptoms of active TB during and after treatment.

Inflammatory Bowel Disease

Inflammatory Bowel Disease Inflammatory Bowel Disease (IBD) exacerbations, in some cases serious and/or leading to discontinuation of COSENTYX, occurred in COSENTYX treated subjects during clinical trials in PsO, PsA, AS, nr-axSpA, and HS. In adult subjects with HS, the incidence of IBD was higher in subjects who received COSENTYX 300 mg every 2 weeks (Ulcerative Colitis [UC] 1 case, EAIR 0.2/100 subject-years; Crohn’s Disease [CD] 1 case, EAIR 0.2/100 subject-years) compared to subjects who received COSENTYX 300 mg every 4 weeks (IBD 1 case, EAIR 0.2/100 subject-years). In addition, new onset IBD cases occurred in subjects treated with COSENTYX in clinical trials. In an exploratory trial in 59 subjects with active Crohn’s disease [COSENTYX is not approved for the treatment of Crohn’s disease], there were trends toward greater disease activity and increased adverse reactions in subjects treated with COSENTYX as compared to placebo-treated subjects.

Exercise caution when prescribing COSENTYX to patients with IBD. Patients treated with COSENTYX should be monitored for signs and symptoms of IBD.

Eczematous Eruptions

In postmarketing reports, cases of severe eczematous eruptions, including atopic dermatitis‑like eruptions, dyshidrotic eczema, and erythroderma, were reported in patients receiving COSENTYX; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of COSENTYX.

Treatment may need to be discontinued to resolve the eczematous eruption. Some patients were successfully treated for eczematous eruptions while continuing COSENTYX.

Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in COSENTYX treated subjects in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable caps of the COSENTYX Sensoready® pen and the COSENTYX 1 mL and 0.5 mL prefilled syringes contain natural rubber latex, which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Immunizations

Prior to initiating therapy with COSENTYX, consider completion of all age-appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient’s immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see full Prescribing Information, including Medication Guide.